•  
  •  
 

Henry Ford Hospital Medical Journal

Abstract

In the past, chemotherapy of renal adenocarcinoma has been relatively unsuccessful. The progestational agent, medroxy progesterone acetate (MPA), has been the most effective single agent, even though the response rate probably does not exceed 12%. This report describes the results of a program of combination therapy with MPA, cyclophosphamide, hydroxyurea, vinblastine and prednisone that was used on 42 patients, ten of whom had received prior MPA therapy. One complete remission and seven partial remissions were observed, oniyone of whom had received prior MPA therapy. Treatment of metastatic renal adenocarcinoma with combination chemotherapy should probably include MPA and adriamycin. The role of estrogen receptor (ER) and progesterone receptor (PR) as predictions of response to hormonal therapy in this disease looks encouraging, but the results reported to date have been limited.

Share

COinS